SCHEMBL16508127

SCHEMBL16508127

CC(C)C[C@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(N)=O)[C@@H](C)O

nearest known ligand 0.53

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ TFPI P10646 1/20 0.51
▸ OPRL1 P41146 2/20 0.47
▸ KEAP1 Q14145 1/20 0.46
▸ IL23R Q5VWK5 1/20 0.44
▸ RAMP3 O60896 6/20 0.43
▸ CALCR P30988 6/20 0.43
▸ VIPR1 P32241 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16507759 0.91 TFPI (0.50) TFPIOPRL1KEAP1IL23RVIPR1
SCHEMBL16507873 0.85 GLP1R (0.45) TFPIOPRL1RAMP3CALCR
SCHEMBL30069111 0.84 TFPI (0.59) TFPIIL23RRAMP3CALCR
SCHEMBL30432032 0.82 OPRL1 (0.48) TFPIOPRL1RAMP3CALCRVIPR1
SCHEMBL16507777 0.82 OPRL1 (0.46) TFPIOPRL1RAMP3CALCR
SCHEMBL16507754 0.82 OPRL1 (0.46) TFPIOPRL1RAMP3CALCR
SCHEMBL16508057 0.82 OPRL1 (0.46) TFPIOPRL1RAMP3CALCR
SCHEMBL30069086 0.82 TFPI (0.61) TFPIVIPR1
SCHEMBL16507762 0.82 TFPI (0.56) TFPIOPRL1RAMP3CALCR
SCHEMBL25455626 0.82 TFPI (0.53) TFPIOPRL1KEAP1IL23RRAMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110294738-A1 PTHR1 RECEPTOR COMPOUNDS ANTHOR THERAPEUTICS, INC. 2011-12-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294738-A1 PTHR1 RECEPTOR COMPOUNDS PTH1R, MC1R, CASR TFPI 2646/4885OPRL1 335/4885KEAP1 3576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback